TFB Advisors LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)

TFB Advisors LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 15,807 shares of the biopharmaceutical company’s stock after purchasing an additional 655 shares during the period. TFB Advisors LLC’s holdings in Pfizer were worth $419,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Certuity LLC grew its position in Pfizer by 170.6% during the fourth quarter. Certuity LLC now owns 150,810 shares of the biopharmaceutical company’s stock valued at $4,001,000 after buying an additional 95,068 shares during the period. Signet Investment Advisory Group Inc. grew its position in shares of Pfizer by 3.5% during the 4th quarter. Signet Investment Advisory Group Inc. now owns 123,186 shares of the biopharmaceutical company’s stock valued at $3,268,000 after acquiring an additional 4,152 shares during the period. Augustine Asset Management Inc. acquired a new position in Pfizer in the 4th quarter worth about $470,000. Reik & CO. LLC boosted its position in Pfizer by 29.0% during the fourth quarter. Reik & CO. LLC now owns 33,336 shares of the biopharmaceutical company’s stock worth $883,000 after purchasing an additional 7,500 shares in the last quarter. Finally, Edmp Inc. grew its holdings in Pfizer by 20.0% in the fourth quarter. Edmp Inc. now owns 13,532 shares of the biopharmaceutical company’s stock valued at $359,000 after purchasing an additional 2,252 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.3 %

NYSE PFE opened at $25.46 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The business’s fifty day simple moving average is $26.28 and its 200-day simple moving average is $27.65. The firm has a market cap of $144.28 billion, a PE ratio of 18.06, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.10 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.76%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 121.99%.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Citigroup decreased their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.